3rd Nordic Conference on Paediatric Medicines

EU Paediatric Regulation (EC 1901/2006) came into force in 2007 with the aim to improve the health of the children in Europe by increasing the research and authorization of medicines for children and improving the information on medicines designed for children. To meet the objectives of the regulation, increasing number of paediatric clinical trials must be conducted. This requires more research capacity; increasing demand for investigators, centres and networks in Europe.

Since 2013, the Pharma Industry Finland together with the Finnish Investigators network for Paediatric Medicines – FinPedMed - have been facilitating academic and Pharma Industry collaboration for paediatric medicine development and clinical trials in the Nordic area. This collaborative conference is third in order following the 2017 and 2018 similar events focusing on paediatric medicines.

Finland's third EU Presidency of the Council of the European Union period begins on 1 July 2019 and lasts to the end of the year. The second half of 2019 will also mark the beginning of the work of the New EU Parliament and Commission. This is important moment for all stakeholders to join the debate on a joint vision about the future parameters for paediatric and orphan medicines.

This 3rd Nordic conference will facilitate and bring forward ideas for discussion in order to accelerate medicine development for children, by providing most appropriate context for new solutions, and updating the current information related paediatric CTs.

3rd Nordic Conference on Paediatric Medicines - Accelerating medicine development for children – Draft

- **What has the Regulation achieved and what can we do to strengthen the system and optimize outcomes for children?**
  - **Thoughts after 10-yrs**
  - **Possible policy options to improve the situation including new, off-patent and rare disease medication**
    - **EU Commission point of view**
    - **Pharma Industry point of view**
    - **Clinician's point of view**
    - **Patient's point of view**
- **Rational age classification for inclusion of developmental subgroups in paediatric studies?**
  - **When does the natural development of adolescents end?**
  - **Is it feasible to include paediatric subpopulations in adult studies – and adult subpopulations in paediatric studies?**
    - **Academic point of view**
    - **Pharma Industry point of view**
- **Update on the European Paediatric Research Infrastructure Initiatives**
- **Young persons as a new stakeholder's group for paediatric medicines development**
- **Potential new funding opportunities for the paediatric clinical research in Nordic Countries**
  - **NordForsk (NordForsk is an organisation under the Nordic Council of Ministers that provides funding for and facilitates Nordic cooperation on research and research infrastructure)**